RC
ESPR

Rangeley Capital’s Esperion Therapeutics ESPR Stock Holding History

Rangeley Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$196K Buy
+62,000
New +$173K 0.18% 121
2025
Q2 		– Sell
-92,500
Closed -$133K – 83
2025
Q1 		$133K Sell
92,500
-14,500
-14% -$26.7K 0.14% 67
2024
Q4 		$235K Buy
+107,000
New +$250K 0.21% 60

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Rangeley Capital's ESPR Position: Q2 2026 in Review

Rangeley Capital opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 62,000 shares worth $196K. The stake represents 0.18% of the portfolio and ranks #121 among its holdings. This is a return to the name: Rangeley Capital previously reported a position in ESPR as recently as Q1 2025.

Rangeley Capital first reported a position in ESPR in Q4 2024 and has held it in 3 quarters since. The position peaked at $235K in Q4 2024. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Rangeley Capital held 62,000 shares of Esperion Therapeutics worth $196K as of Q2 2026.
  • Esperion Therapeutics was a new Rangeley Capital position in Q2 2026.
  • Esperion Therapeutics made up 0.18% of Rangeley Capital's portfolio in Q2 2026, its #121 holding.
  • Rangeley Capital first reported a position in Esperion Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • Rangeley Capital's Esperion Therapeutics position peaked at $235K in Q4 2024.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.